Paraquat is a restricted-use herbicide manufactured primarily by Syngenta and distributed by Chevron Phillips Chemical and Growmark. Despite being banned in more than 70 countries including the European Union, China, Brazil, and Thailand, paraquat remains legal in the United States, where approximately 10 million pounds are applied annually. Scientific evidence — including the landmark Farming and Movement Evaluation (FAME) study published in 2011 — demonstrates that paraquat exposure increases the risk of Parkinson’s disease by 2.5 times. The mechanism is well understood: paraquat triggers oxidative stress through redox cycling, inhibits mitochondrial complex I, and selectively kills dopamine-producing neurons in the substantia nigra, leading to the progressive motor and cognitive deterioration characteristic of Parkinson’s disease. MDL 3004 was established in June 2021 in the Southern District of Illinois, with approximately 5,000 cases pending. Bellwether proceedings and settlement negotiations are ongoing, with projected individual settlements ranging from $20,000 to over $1,000,000 depending on disease severity and exposure documentation.
Litigation Timeline
Mertens Bellwether Settles; Litigation Pause Extended
The Mertens v. Syngenta bellwether case settles on the eve of a Philadelphia trial on January 28–29, 2026, with confidential terms. This follows two earlier Philadelphia state court settlements in July and October 2025. A broader framework settlement agreement had been reached in April 2025. The litigation pause has been extended through March 6, 2026, as the parties work toward comprehensive resolution of the remaining approximately 5,000 cases.
settlementDaubert Ruling; EPA Registration Review
Judge Rosenstengel issues a Daubert ruling excluding the testimony of Dr. Martin Wells, a statistician, leading to the dismissal of four bellwether cases on April 17, 2024. Separately, the EPA completes its registration review of paraquat, reaffirming the herbicide’s registration despite submissions of 90 studies by the Michael J. Fox Foundation. The Daubert ruling, while a setback, does not affect the broader scientific evidence available through other expert witnesses.
verdictDorsey Agnotology Paper Published
Dr. Ray Dorsey and colleagues publish a landmark paper documenting what they term "agnotology" — the deliberate production of ignorance — by Syngenta regarding the paraquat-Parkinson’s connection. The paper systematically catalogues Syngenta’s "Scientific Influencing Strategy," suppression of the Louise Marks studies, targeting of independent researchers, and use of reputation management firms. The paper draws explicit parallels to the tobacco industry’s decades-long campaign to deny the link between smoking and cancer.
verdictMDL 3004 Established; Syngenta $187.5M Settlement
The Judicial Panel on Multidistrict Litigation consolidates paraquat Parkinson’s cases in the Southern District of Illinois before Judge Nancy J. Rosenstengel (MDL 3004). Syngenta simultaneously announces a $187.5 million initial settlement fund. The MDL consolidation signals the scale and seriousness of the litigation, with thousands of cases from across the country coordinated for pre-trial proceedings.
settlementChina Bans Paraquat; First U.S. Lawsuits Filed
China bans all domestic paraquat sales and use, the same year ChemChina acquires Syngenta for $43 billion. The first U.S. lawsuits alleging that paraquat exposure caused Parkinson’s disease are filed in federal courts. The combination of international bans, strong scientific evidence, and newly available internal corporate documents creates the conditions for mass litigation.
filingFAME Study Published: 2.5x Parkinson’s Risk
The landmark Farming and Movement Evaluation (FAME) study, led by Dr. Caroline Tanner and published in Environmental Health Perspectives, finds that paraquat users have a 2.5-fold (250%) increased risk of developing Parkinson’s disease compared to non-users. The study’s use of detailed pesticide use records rather than self-reported data gives it exceptional methodological rigor. The FAME study becomes the cornerstone of plaintiffs’ causation arguments in the litigation.
filingEuropean Union Bans Paraquat
The European Commission declines to renew paraquat’s authorization under Directive 91/414/EEC (Decision 2007/442/EC), effectively banning the herbicide throughout the EU. The decision cited unacceptable risks to operators and bystanders, including evidence of neurotoxicity. The EU ban was upheld by the European Court of Justice in 2008 and is frequently cited in the U.S. litigation as evidence that international regulators reached more protective conclusions than the EPA.
regulatorySyngenta Formed from ICI/Zeneca Merger
ICI’s agrochemical division (via Zeneca) merges with Novartis’s crop science division to form Syngenta AG, headquartered in Basel, Switzerland. Syngenta inherits ICI’s paraquat product line, manufacturing operations, and accumulated internal research documenting neurotoxicity — including the suppressed Louise Marks studies showing substantia nigra damage.
product-launchEPA Classifies Paraquat as Restricted Use Pesticide
The U.S. Environmental Protection Agency classifies paraquat as a Restricted Use Pesticide (RUP) due to its acute toxicity, limiting purchase and application to licensed certified applicators. The restriction acknowledged paraquat’s danger but focused on acute poisoning risk rather than chronic neurological effects. The RUP classification remains in effect today.
regulatoryParaquat Marketed Commercially by ICI
Imperial Chemical Industries (ICI) begins commercial marketing of paraquat as a broad-spectrum contact herbicide. ICI’s own internal research had already identified neurotoxic properties of the compound as early as 1958 and confirmed that paraquat enters the brain in mice by 1966. Despite this knowledge, ICI marketed paraquat without neurological warnings for decades.
product-launchNotable Verdicts & Settlements
Syngenta Initial Settlement (MDL 3004)
SettlementSyngenta agreed to establish a $187.5 million initial settlement fund at the time of MDL 3004’s formation in June 2021. The fund was created to resolve early-filing paraquat Parkinson’s claims and demonstrated Syngenta’s recognition of significant liability exposure. The settlement marked the first major financial resolution in the paraquat litigation and established a baseline for case valuations.
MDL 3004 Framework Settlement Agreement
SettlementIn April 2025, the parties in MDL 3004 reached a broader framework settlement agreement to resolve the remaining approximately 5,000 pending cases. The specific financial terms of the agreement remain confidential, but the framework establishes the structure for individual case resolution including tier-based compensation, documentation requirements, and claims administration procedures. The agreement represents a significant milestone in the litigation’s progression toward comprehensive resolution.
Mertens v. Syngenta (Bellwether Settlement)
SettlementThe Mertens v. Syngenta bellwether case settled on the eve of trial in Philadelphia on January 28–29, 2026, with confidential terms. The case had been selected as a bellwether to test plaintiffs’ causation theory and damages evidence before a jury. The pre-trial settlement signals the defendants’ assessment that trial posed significant risk and provides momentum for resolution of the broader MDL.
Philadelphia State Court Settlement I
SettlementThe first of two Philadelphia state court paraquat Parkinson’s cases settled pre-trial in July 2025 with confidential terms. Philadelphia’s Complex Litigation Center has been an active venue for paraquat litigation alongside the federal MDL. The pre-trial settlement was reached after completion of discovery and expert depositions, suggesting the evidence was sufficiently compelling to motivate resolution.
Philadelphia State Court Settlement II
SettlementA second Philadelphia state court paraquat case settled pre-trial in October 2025, continuing the pattern of defendants resolving cases before they reach juries. The consecutive Philadelphia settlements, combined with the Mertens bellwether settlement in January 2026, demonstrate sustained settlement momentum and defendants’ reluctance to risk adverse jury verdicts.
Daubert Ruling — Dr. Wells Expert Exclusion
Jury VerdictJudge Rosenstengel excluded the expert testimony of Dr. Martin Wells, a Cornell University statistician, under the Daubert standard. The ruling found that Dr. Wells’s statistical methodology did not meet the reliability requirements for admissibility. As a result, four bellwether cases that relied heavily on Dr. Wells’s testimony were dismissed on April 17, 2024. While a significant setback for the affected cases, the ruling does not impact the broader body of epidemiological, toxicological, and mechanistic evidence available through other expert witnesses. The FAME study, Pezzoli meta-analysis, and mechanistic research remain admissible through qualified experts.
Comparable: Roundup/Glyphosate Verdicts (Bayer)
SettlementWhile not a paraquat case, the Roundup/glyphosate litigation provides the most directly comparable precedent for pesticide-cancer/neurodegenerative disease mass torts. Bayer agreed to pay approximately $10.9 billion to settle over 100,000 Roundup claims alleging the herbicide caused non-Hodgkin lymphoma. Individual jury verdicts in the Roundup cases ranged from $80 million to $2 billion before reductions. The Roundup litigation demonstrates that pesticide manufacturers face massive liability exposure when scientific evidence, internal corporate documents, and failure-to-warn claims converge — the same combination present in the paraquat litigation.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full Paraquat Parkinson’s Case Page